Structure Therapeutics Inc. (GPCR)
NASDAQ: GPCR · Real-Time Price · USD
58.81
-4.32 (-6.84%)
Mar 5, 2026, 2:16 PM EST - Market open
Structure Therapeutics Stock Forecast
Stock Price Forecast
The 11 analysts with 12-month price forecasts for Structure Therapeutics stock have an average target of 104.64, with a low estimate of 65 and a high estimate of 140. The average target predicts an increase of 77.93% from the current stock price of 58.81.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Structure Therapeutics stock from 11 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 7 | 7 | 7 | 7 |
| Buy | 4 | 4 | 4 | 5 | 5 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 11 | 12 | 12 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $90 → $114 | Strong Buy | Maintains | $90 → $114 | +93.84% | Mar 2, 2026 |
| Citizens | Citizens | Buy Maintains $120 → $113 | Buy | Maintains | $120 → $113 | +92.14% | Feb 27, 2026 |
| JP Morgan | JP Morgan | Buy Maintains $65 → $105 | Buy | Maintains | $65 → $105 | +78.54% | Jan 22, 2026 |
| Guggenheim | Guggenheim | Strong Buy Maintains $90 → $140 | Strong Buy | Maintains | $90 → $140 | +138.05% | Jan 20, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $60 → $90 | Strong Buy | Maintains | $60 → $90 | +53.04% | Dec 19, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
15.40B
EPS This Year
-1.75
from -2.39
EPS Next Year
-2.16
from -1.75
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | n/a | 158.6B | |||
| Avg | n/a | 15.4B | |||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -1.39 | -1.72 | |||
| Avg | -1.75 | -2.16 | |||
| Low | -2.19 | -2.86 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.